3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Uveal Melanoma
2
Lymphoma, T-Cell, Cutaneous
2
Lichen Planus, Oral
2
Stomach Neoplasms
1
Retinal Diseases
1
Recurrence
1
Radiodermatitis
1
Pain
1
Neuroma, Acoustic
1
Mycosis Fungoides
1
Melanoma
1
Macular Degeneration
1
Lymphomatoid Papulosis
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Leiomyoma
1
Glioblastoma
1
Fibroma
1
Exanthema
1
Esophageal Stenosis Acquired
1
Dupuytren Contracture
1
Disease
1
Dermatitis, Contact
1
Choroid Diseases
1
Chalazion
1
Castration Resistant Prostate Cancer
1
Breast Neoplasms
1
Adenomyosis
1
Interventions
bintrafusp alfa protein, human
1
Triamcinolone Acetonide
1
TH 302
1
Specimen Handling
1
Magnetic Resonance Spectroscopy
1
Injections, Intramuscular
1
ALT-803
1
AGN 194204
1
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Castration Resistant Prostate Cancer
×
Triamcinolone Acetonide
×
Clear all
NCT07161778
2025-09-09
TRICREST
Barts & The London NHS Trust
Phase 2
Completed
55 enrolled